What was the market valuation of the US membranous nephropathy market in 2024?

The market valuation was $73.5 Million in 2024. Read More

What is the projected market valuation for the US membranous nephropathy market by 2035?

The projected valuation for 2035 is $125.0 Million. Read More

What is the expected CAGR for the US membranous nephropathy market during the forecast period 2025 - 2035?

The expected CAGR during this period is 4.95%. Read More

Which companies are considered key players in the US membranous nephropathy market?

Key players include Roche, Novartis, Bristol-Myers Squibb, Pfizer, Sanofi, AstraZeneca, Gilead Sciences, and Merck & Co. Read More

What are the primary and secondary product type segments in the US membranous nephropathy market?

The primary segment ranges from $40.0 to $70.0 Million, while the secondary segment ranges from $33.5 to $55.0 Million. Read More

What types of therapies are included in the US membranous nephropathy market?

Therapies include Conservative Therapy ($20.0 to $35.0 Million), Non-Immunosuppressive Therapy ($25.0 to $40.0 Million), and Immunosuppressive Therapy ($28.5 to $50.0 Million). Read More

What are the material type segments in the US membranous nephropathy market?

Material types include Urine Tests ($15.0 to $25.0 Million), Blood Tests ($20.0 to $35.0 Million), Glomerular Filtration Rate Tests ($25.0 to $40.0 Million), and Antinuclear Antibody Tests ($13.5 to $25.0 Million). Read More

How does the market size in 2035 compare to that in 2024?

The market size in 2035 is projected to be $125.0 Million, an increase from $73.5 Million in 2024. Read More

What factors might influence the growth of the US membranous nephropathy market?

Factors influencing growth may include advancements in treatment options, increased awareness, and the rising prevalence of membranous nephropathy. Read More

What is the significance of the projected growth rate for the US membranous nephropathy market?

The projected growth rate of 4.95% indicates a steady expansion, reflecting ongoing developments in therapies and diagnostics. Read More

US Membranous Nephropathy Market

ID: MRFR/Pharma/17374-HCR

100 Pages

Vikita Thakur

Last Updated: April 06, 2026

US Membranous Nephropathy Market Research Report By Product Type (Primary, Secondary), By Type (Conservative Therapy, Non-immunosuppressive Therapy, Immunosuppressive Therapy) and By Material Type (Urine Test, Blood Test, Glomerular Filtration Rate Test, Antinuclear Antibody Test) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Product Type (USD Million)
  1. 4.1.1 Primary
  2. 4.1.2 Secondary
2. 4.2 Pharmaceutical, BY Type (USD Million)
  1. 4.2.1 Conservative Therapy
  2. 4.2.2 Non-Immunosuppressive Therapy
  3. 4.2.3 Immunosuppressive Therapy
3. 4.3 Pharmaceutical, BY Material Type (USD Million)
  1. 4.3.1 Urine Tests (Urinalysis)
  2. 4.3.2 Blood Tests
  3. 4.3.3 Glomerular Filtration Rate Tests
  4. 4.3.4 Antinuclear Antibody Tests
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sanofi (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Gilead Sciences (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck & Co. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY PRODUCT TYPE
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY MATERIAL TYPE
5. 6.5 KEY BUYING CRITERIA OF PHARMACEUTICAL
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF PHARMACEUTICAL
8. 6.8 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
9. 6.9 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
11. 6.11 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 (% SHARE)
12. 6.12 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 TO 2035 (USD Million)
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
14. 6.14 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
15. 6.15 PHARMACEUTICAL, BY MATERIAL TYPE, 2024 (% SHARE)
16. 6.16 PHARMACEUTICAL, BY MATERIAL TYPE, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PRODUCT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY MATERIAL TYPE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Pharmaceutical Market Segmentation

Pharmaceutical By Product Type (USD Million, 2025-2035)

Primary
Secondary

Pharmaceutical By Type (USD Million, 2025-2035)

Conservative Therapy
Non-Immunosuppressive Therapy
Immunosuppressive Therapy

Pharmaceutical By Material Type (USD Million, 2025-2035)

Urine Tests (Urinalysis)
Blood Tests
Glomerular Filtration Rate Tests
Antinuclear Antibody Tests

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”